UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| | ||
(Exact name of registrant as specified in its charter) | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File
Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class: | Trading Symbol | Name of Each Exchange on which Registered |
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On November 17, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of clinical data from the Phase 1b clinical study of rexaceract. As of November 1, 2026, all 13 evaluable patients in the Phase 1b clinical study have completed the full 12-month administration of rexaceract, comprising the 3-month Part 1 of the study and the 9-month open-label extension. MDS-UPDRS motor scores demonstrated stability when compared to baseline with no overall disease progression as measured by the MDS-UPDRS Parts II and III scales among the 13 evaluable participants who had completed 12 months of daily oral administration of rexaceract. Following the first 3 months (90 days) of dosing, all 11 evaluable patients with Parkinson's disease, and from whom the Company had evaluable cerebrospinal fluid (CSF) samples, demonstrated reductions or no change in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) levels from baseline. One participant was subsequently diagnosed with multiple system atrophy (MSA). This participant demonstrated a change in CSF GluSph in the opposite direction. This participant also did not demonstrate a meaningful clinical response to treatment.
Long-term data demonstrated that rexaceract is generally well tolerated over 12 months of dosing. No new safety concerns were identified during Part 2 (the 9-month extension) Data Monitoring Committee reviews and overall, a lower incidence of Treatment-Emergent Adverse Events (TEAEs) occurred in Part 2 of the study compared with Part 1 (initial three-month administration). Additionally, no new clinically relevant liver enzyme elevations were observed with continued dosing for up to 1 year.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GAIN THERAPEUTICS, INC. | ||
| Dated: November 17, 2026 | By: | /s/ Gene Mack |
| Gene Mack | ||
| Chief Executive Officer | ||